Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | GYS1 | P13807 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991992 | 0.90 | PARP15 (0.39) | PARP15PARP10HCRTR2 | |
| SCHEMBL21992679 | 0.88 | HIF1A (0.40) | TDP1L3MBTL1PARP15PARP10HIF1A | |
| SCHEMBL23605986 | 0.86 | FFAR1 (0.43) | PARP15PARP10FFAR1 | |
| SCHEMBL21991810 | 0.82 | TDP1 (0.42) | TDP1L3MBTL1FFAR1GRM4 | |
| SCHEMBL21991332 | 0.81 | CYP2C9 (0.46) | TDP1L3MBTL1 | |
| SCHEMBL21991929 | 0.80 | MAPT (0.40) | — | |
| SCHEMBL23605941 | 0.79 | POLB (0.44) | TDP1L3MBTL1GRM4 | |
| SCHEMBL21992706 | 0.77 | CYP1A2 (0.49) | TDP1 | |
| SCHEMBL21991801 | 0.77 | PDE3B (0.42) | L3MBTL1PARP15PARP10HIF1AFFAR1 | |
| SCHEMBL21992716 | 0.76 | MTNR1B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885PARP15 1242/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885PARP15 1242/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885PARP15 1242/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885PARP15 1242/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885PARP15 1242/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TDP1 1445/4885L3MBTL1 1170/4885PARP15 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.